Condition: Head and Neck Cancer · Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
To develop postoperative stratification treatment for patients who have received induction chemotherapy and immunotherapy in locally advanced head and neck cancers. Risk stratification is based on clinical characteristics and pathological responses. In order to achieve no inferior survival rate and a lower treatment-related toxicity rate than the standard treatment.
This description comes directly from the study's public registry record.
Yi Xu · 15811166516 · 694818945@qq.com
Always discuss trial participation with your own doctor first.
| National Cancer Center /National Clinical Research Center for Cancer/Cancer Hospital, CAMS & PUMC | Beijin, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05777824